SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-22-071165
Filing Date
2022-11-10
Accepted
2022-11-10 16:09:24
Documents
75
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0922_jasperthera.htm   iXBRL 10-Q 1467330
2 CONTROLLED EQUITY OFFERINGSM SALES AGREEMENT, DATED AS OF NOVEMBER 10, 2022, BY f10q0922ex10-1_jasperthera.htm EX-10.1 236334
3 CERTIFICATION f10q0922ex31-1_jasperthera.htm EX-31.1 10739
4 CERTIFICATION f10q0922ex31-2_jasperthera.htm EX-31.2 10476
5 CERTIFICATION f10q0922ex32-1_jasperthera.htm EX-32.1 6728
  Complete submission text file 0001213900-22-071165.txt   6192477

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE jspr-20220930.xsd EX-101.SCH 67274
7 XBRL CALCULATION FILE jspr-20220930_cal.xml EX-101.CAL 28008
8 XBRL DEFINITION FILE jspr-20220930_def.xml EX-101.DEF 261756
9 XBRL LABEL FILE jspr-20220930_lab.xml EX-101.LAB 549009
10 XBRL PRESENTATION FILE jspr-20220930_pre.xml EX-101.PRE 280436
69 EXTRACTED XBRL INSTANCE DOCUMENT f10q0922_jasperthera_htm.xml XML 632497
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

IRS No.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39138 | Film No.: 221377197
SIC: 2836 Biological Products, (No Diagnostic Substances)